SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is seeing heightened community engagement as investors monitor its potential role in the growing real-world asset and stablecoin integration, with many debating the impact of regulatory clarity on its future adoption. While some participants are actively accumulating the asset, discussion remains divided between those expecting a significant long-term breakout and others frustrated by recent price stagnation.

iShares Trust - iShares 0-3 Month Treasury Bond ETF

iShares 0-3 Month Treasury Bond ETF

Investors are increasingly flocking to SGOV as a defensive parking spot to preserve capital and earn steady interest while navigating broad market volatility and uncertain economic data. The community remains focused on using the ETF as a liquidity tool to wait out market turbulence while closely monitoring inflation trends and Federal Reserve policy shifts.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is gaining traction as community members highlight a relentless, organic grind focused on expanding the project's IRL presence through diverse initiatives like racing, merchandise, and food products. Investors remain highly active in discussing their conviction and long-term commitment, framing the current market environment as a strategic opportunity to accumulate and build.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased investor attention as the community debates its long-term potential, with bulls pointing to the token's institutional integrations and quantum-resistant technology as key value drivers. While some participants are actively accumulating at lower price levels, others remain skeptical, fueling a polarizing discussion on social forums regarding the project's ability to achieve significant growth in the current market cycle.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

Internet Computer (ICP) is attracting significant attention as investors shift toward projects with tangible AI infrastructure and decentralized cloud capabilities, distancing the asset from speculative meme-driven narratives. Community sentiment is increasingly divided between those betting on long-term adoption through its sovereign cloud and on-chain AI integrations, and critics citing historical volatility and inflationary tokenomics as major headwinds.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment focuses on branded generic pharmaceuticals that are manufactured worldwide and marketed and sold outside the United States, primarily in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternative care testing sites. The Nutritional Products segment oversees the worldwide sale of pediatric and adult nutritional products. The Medical Devices segment offers a broad range of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, as well as diabetes care and continuous glucose monitoring products. It also provides neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

Abbott Laboratories is trending as the market evaluates its recent earnings report, with sentiment divided between concerns over nutrition segment performance and optimism surrounding the company's long-term medical device and oncology diagnostic growth. The community is actively debating whether the stock's recent valuation represents a significant entry opportunity for a defensive healthcare giant or if underlying legal and acquisition-related headwinds could lead to further consolidation.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as investors debate whether the token is a long-term utility play or a failed project, with sentiment split between persistent 'bagholders' accumulating at lower prices and critics calling out its steep long-term decline. While some community members look to potential regulatory clarity and institutional adoption for a reversal, others are actively mocking the project's performance and leadership's communication strategy.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is currently facing significant selling pressure from whales, sparking heated debate among community members over whether this represents a manipulation tactic or a genuine failure of the project's long-term thesis. While some investors view the recent price drop as a generational buying opportunity tied to potential Middle East and institutional partnerships, others are increasingly vocal about their lack of trust in leadership and concerns regarding the actual network utility.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently a focal point for investors as the company prepares for upcoming presentations in mid-May that aim to showcase new clinical data for their lead candidate, soquelitinib. The community is actively debating the stock's potential for a significant squeeze, fueled by high short interest and growing institutional ownership, with many focused on whether recent analyst attention and strategic board appointments indicate a broader rerating for the biotech firm.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap is trending as the community rallies behind a major governance proposal to activate a fee switch and initiate a significant token burn, fueling strong optimism around the protocol's long-term deflationary potential. Traders are actively debating the timing of this shift while monitoring institutional interest and technical momentum as the token attempts to break through key resistance levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tempus AI's FDA Win Could Unlock Major Reimbursement Growth Ahead

TEM's FDA approval for xT could unlock $85 million in annual revenue from higher pricing, with bigger gains tied to xF.

Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High?

TEM's faster growth, rising data demand and reimbursement potential strengthen the bull case, but high valuation and cash burn keep risks in focus.

Tempus Q2 Earnings Call Highlights Data Growth and Pricing Upside

TEM raises its 2026 revenue outlook as oncology testing, data demand and FDA-linked pricing gains support growth and cash flow improvement.


Why Is Tempus AI Stock Surging on Friday?

Tempus AI Inc. (NASDAQ: TEM) stock jumped on Friday, August 7, 2026, following strong AI healthcare peer earnings from Doximity Inc. and a strategic lab expansion with CellCarta.read more...

Can Weight-Loss Momentum Lift Hims & Hers Stock Before Q2 Earnings?

HIMS' second-quarter 2026 results are likely to benefit from weight-loss demand and global expansion even as margin pressures and higher spending linger.

CellCarta Adds Tempus to CDx Commercialization Lab Network

CellCarta Adds Tempus to CDx Commercialization Lab Network CellCarta Adds Tempus to CDx Commercialization Lab Network PR Newswire MONTREAL, Aug. 6, 2026 Tempus joins as a second commercial laboratory partnership to support oncology-focused access within CellCarta's CDx Accelerator Model.MONTREAL...

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced study results demonstrating that PRISM2, a multimodal slide-level pathology foundation model developed in collaboration with researchers from Microsoft, can...

TEM Q2 Loss Narrower Than Expected, Revenues Beat, Stock Up

Tempus AI climbs 6.6% after its second-quarter loss narrows, revenues beat estimates and 2026 sales guidance rises on diagnostics and data growth.

Compared to Estimates, Tempus (TEM) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Tempus (TEM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Tempus AI (TEM) Reports Q2 Loss, Beats Revenue Estimates

Tempus (TEM) delivered earnings and revenue surprises of +69.23% and +0.40%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

This account has been verified as an official TEM representative.

Verified Account

Tempus AI

$TEM Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.03 up 112.00% YoY
• Reported revenue of $382.49M up 21.56% YoY

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

TEM, PSNL Stocks Are Falling — Why Morgan Stanley Still Likes Tempus AI’s Personalis Deal

Equity

Neutral Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.07	--	--	N/A
Q2 '26	-$0.14	-$0.04	72.03%	BEAT
Q1 '26	-$0.20	-$0.13	34.87%	BEAT
Q4 '25	-$0.04	-$0.04	3.48%	BEAT
Q3 '25	-$0.17	-$0.11	36.15%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings